Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: Influence on portal hypertension

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 7, 2011, Pages 573-577

  Elia, Chiara ^a   Venon, Wilma Debernardi ^a   Stradella, Davide ^a   Martini, Silvia ^a   Brunello, Franco ^a   Marzano, Alfredo ^a   Saracco, Giorgio ^b   Rizzetto, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SC Gastroenterology San Luigi Gonzaga Hospital   (Italy)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Portal hypertension; Transcatheter arterial chemoembolization

Indexed keywords

CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; ASCITES; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DISEASE COURSE; ESOPHAGUS VARICES BLEEDING; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DOXORUBICIN; ESOPHAGEAL AND GASTRIC VARICES; ETHIODIZED OIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79960109324     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834701f5     Document Type: Article

References (28)

1. Borsch FX, Ribes J, Diaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127 (Suppl 1):5-17.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice guidelines committee, American association for the study of liver diseases. Hepatology 2005; 42:1208-1236.
3. Llovet JM, Bruix J. Novel advancement in the management in hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl 1):S20-S37.
4. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1):S179-S188. (Pubitemid 39423386)
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429-442. (Pubitemid 36152543)
6. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018-1022. (Pubitemid 26327605)
7. Okada K, Koda M, Murawaki H, Kawasaki H. Changes in esophageal variceal pressure after transcatheter arterial embolization for hepatocellular carcinoma. Endoscopy 2001; 33:595-600. (Pubitemid 32618926)
8. Moriyasu F, Ban N, Nishida O, Nakamura T, Soh Y, Miura K, et al. Portal hemodynamics in patients with hepatocellular carcinoma. Radiology 1986; 161:707-711. (Pubitemid 17200422)
9. Taourel P, Dauzat M, Lafortune M, Pradel J, Rossi M, Bruel JM. Hemodynamic changes after transcatheter arterial embolization of hepatocellular carcinomas. Radiology 1994; 191:189-192.
10. Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4:1378-1384. (Pubitemid 44781090)
11. Kadouchi K, Higuchi K, Shiba M, Okazaki H, Yamamori K, Sasaki E, et al. What are the risk factors for aggravation of esophageal varices in patients with hepatocellular carcinoma? J Gastroenterol Hepatol 2007; 22:240-246. (Pubitemid 46181355)
12. Hatashi S. Clinical evaluation of prophylactic sclerotherapy for esophageal varices in patients with unresectable hepatocellular carcinoma-based on patients treated with transcatheter arterial embolization. Nippon Shokakibyo Gakkai Zasshi 1995; 92:47-55.
13. Hsu CY, Huang YH, Su WC, Chiang JH, Lin HC, Lee PC. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J Clin Gastroenterology 2010; 44:e171-e177.
14. Hsu CY, Huang YH, Su CW, Lin HC, Chiang JH, Lee PC. Renal failure in patient with HCC and ascites undergoing transarterial chemoembolization. Liver Int 2009; 1478-3223.
15. Pietrosi G, Miraglia R, Angelo L, Vizzini GB, Fili D, Volpes R, et al. Arterial chemoembolization /embolization and early complications after hepatocellular carcinoma treatment: A safe standardized protocol in selected patients with class A and B cirrhosis. J Vasc Interv Radiol 2009; 20:896-902.
16. Nakano R, Iwao T, Oho K, Ono N, Sakai T, Sato M, et al. Effect of transcatheter arterial chemoembolization on kidney hemodynamics and function in patients with cirrhosis and hepatocellular carcinoma. J Hepatol 1999; 31:340-346. (Pubitemid 29349762)
17. Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: A prospective study. Liver Int 2004; 24:210-215.
18. Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981; 27:213-218. (Pubitemid 12242593)
19. Bosch J, Mastai R, Kravetz D, Navasa M, Rodes J. Hemodynamic evaluation of the patients with portal hypertension. Semin Liver Dis 1986; 6:309-317. (Pubitemid 17219026)
20. Bosch J, Abraldes JG, Groszmann RJ. Current management of portal hypertension. J Hepatol 2003; 38:S54-S68.
21. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397-401. (Pubitemid 13073577)
22. Iton Y, Okanoue T, Ohnishi N, Nishioji K, Sakamoto S, Nagao Y, et al. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver 1999; 19:97-103. (Pubitemid 29139761)
23. Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer 1994; 73:53-57. (Pubitemid 24012721)
24. Spahr L, Becker C, Pugin J, Majno P, Hadengue A. Acute portal hemodynamics and cytokine changes following selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma. Med Sci Monit 2003; 9:CR383-CR388. (Pubitemid 37295232)
25. Lin DY, Hung CF, Chen PC,Wu CS. Gastrointestinal bleeding after hepatic transcatheter arterial embolization in patients with hepatocellular carcinoma. Gastrointest Endosc 1996; 43 (2 Pt 1):132-137.
26. Desautels SG, Slivka A, Schoen RE, Carr B, Rabinovitz M, Silverman W. Gastrointestinal bleeding in cirrhotic patients with hepatocellular carcinoma undergoing intrahepatic artery chemotherapy. Gastrointest Endosc 1997; 46:430-434. (Pubitemid 27498390)
27. Chen WC, Hou MC, Lin HC, Yeh YY, Chang FY, Lee SD. Feasibility and potential benefit of maintenance endoscopic variceal ligation in patients with unresectable hepatocellular carcinoma and acute esophageal variceal hemorrhage: A controlled trial. Gastrointest Endosc 2001; 54 (Suppl 1):18-12.
28. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: A 20-year multicentre experience. Gut 2010; 59 (Suppl 3):387-396.